A novel preclinical model for rheumatoid arthritis research by Petersen, Frank & Yu, Xinhua
In the previous issue, Vierboom and colleagues [1] report 
on a novel animal model of rheumatoid arthritis (RA) 
induced in common marmosets by immunization with 
bovine/chicken type II collagen (CII). As a cartilage-
speciﬁ   c protein, CII is constitutively expressed in the 
synovial joint, which is the tissue predominantly aﬀ  ected 
in RA. CII has been suspected to be an important 
autoantigen and was used to establish several animal 
models of RA. In 1977, the ﬁ  rst collagen-induced arthritis 
(CIA) model was established in rats by immunization with 
CII [2]. Subsequently, this CIA model was reproduced in 
mouse and monkey in 1980 and 1986, respectively [3,4]. 
Th   e essential hallmarks of CIA - for example autoimmune 
response-mediated synovitis and subsequent erosion in 
cartilage and bone - resemble RA, which makes it the most 
widely used animal model for RA research.
Th   e rodent model of CIA has been extensively used for 
investigation of the pathogenesis of the disease and the 
identiﬁ   cation of novel therapeutics and for preclinical 
studies in RA research. Due to a large evolutionary 
distance (Figure 1), considerable diﬀ  erences  between 
humans and rodents are obvious [5]. Th  ese diﬀ  erences 
limit the signiﬁ  cance and validity of rodent models in the 
preclinical evaluation of some therapeutics, especially 
those with species-speciﬁ  c eﬀ  ects [6]. Th  erefore, estab-
lished non-human primate models in macaques can be 
clearly favoured as preclinical models of CIA [7,8]. 
However, despite their advantages, the limitations of 
these monkey models, such as a low incidence of the 
disease, an acute but not chronic type of inﬂ  ammation, as 
well as the large body size of the animals, hamper their 
usability in preclinical studies.
Aiming to develop a novel non-human primate model 
of CIA that overcomes the limitations of the pre-existing 
macaque models, Vierboom and colleagues investigated 
the common marmoset, a small-sized primate that has 
already been studied in models of experimental auto-
immune encephalomyelitis. Common marmosets immu-
nized with either bovine or chicken CII developed 
autoimmune arthritis with very high incidence (21 out of 
the 22 experimental animals). Half of the animals 
developed acute transient arthritis, while the other half 
was characterized by chronic arthritis. Analysis of T cells 
and anti-CII antibodies suggests that both cellular and 
humoral immune responses are involved in the develop-
ment of the disease. Due to the lack of suitable detection 
reagents, C-reactive protein as a biomarker of inﬂ  amma-
tion could not be determined. However, excreted lysyl-
pyridinolines as biomarkers of bone erosion were ob-
served in animals with severe disease.
Abstract
Based on increasing knowledge on the pathogenesis 
of rheumatoid arthritis (RA), more and more potential 
therapeutics have been developed. To evaluate their 
therapeutic effi   cacy, safety and toxicity, appropriate 
animal models are required. Although rodent models 
of RA have been extensively used for preclinical 
evaluation, the diff  erences between rodents and 
humans limit their usability for some species-specifi  c 
therapeutics. Therefore, autoimmune arthritis 
developed in a non-human primate with essential 
hallmarks of RA will be an alternative model for 
preclinical studies.
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Figure 1. Phylogenetic tree of animal species used in CIA. The 
phylogenetic tree was generated based on mitochondrial DNA 
sequences (whole mtDNA except the D-loop region) of the species 
indicated using ClustalW2 software [13].
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monkeys, with the exception of that induced in DA rat 
with rat CII [9]. Unlike autologous CII, heterologous CII 
can only occasionally induce autoreactive T cells in some 
animal strains. Although both heteroreactive and auto-
reactive T cells can help B cells to produce autoantibodies 
to CII and subsequently induce arthritis, the involvement 
of autoreactive T cells makes a signiﬁ  cant diﬀ  erence in 
the pathogenesis of CIA [10] and the latter cell type 
should be characterized in a new model of CIA. Th  e 
authors provided evidence of the presence of hetero-
reactive T cells in marmosets with severe disease, but 
clear proof of the presence of autoreactive T cells is miss-
ing. Together with identiﬁ   cation of the corres  pond  ing 
immunogenic T cell epitopes, more detailed charac  teri-
zation will signiﬁ  cantly increase the impact of this model.
Compared to the macaque models, the marmoset 
model of CIA shows several advantages. First of all, 
common marmosets are smaller and reach their adult age 
earlier than macaques, which saves capacity in animal 
facilities and reduces the amounts of tested substances in 
experiments. Second, the incidence of CIA in common 
marmosets is higher (>95%) than that in macaques (40 to 
60% in rhesus monkey). Both common marmosets and 
macaques are natural outbreds. Th  e surprisingly high 
incidence observed in common marmosets, which might 
be due to a limited variability in their major histocom-
pati  bility complex loci [11], allows the evaluation of the 
eﬃ   cacy of therapeutics using a small number of animals. 
Finally, in contrast to macaques, half of the common 
marmosets developed chronic arthritis. Th  is chronic 
arthritis resembles strongly the pathology in humans and 
provides a wide time window for clinical treatment studies.
It is also interesting to note that marmosets are born as 
bone marrow chimeric twins [12], which are immuno-
logically highly comparable. Th   is unique nature allows a 
paired experimental setting, with one sibling treated with 
therapeutics and the other treated with placebo, which 
may be a valuable tool in preclinical studies.
Aside from the advantages of using marmosets, a main 
drawback of this model should be considered. Th  e 
evolutionary distance between marmosets and humans is 
signiﬁ   cantly larger than that between macaques and 
humans (Figure 1). Compared to macaques, marmosets 
diﬀ   er much more from humans with regard to their 
physiology and immunology. Th  ese physiological diﬀ  er-
ences may limit their validity in safety and toxicity tests. 
Disparities between humans and marmosets in the 
immune system will decrease the cross-reactivity of 
human-speciﬁ  c therapeutics and, furthermore, increase 
the immunogenicity of such therapeutics, which may 
result in the formation of neutralizing antibodies.
In conclusion, experimental CIA in marmosets 
provides a novel and promising non-human primate 
model of RA for preclinical research. With regard to its 
experimental handling and practicability, as well as its 
evolutionary distance from humans, this model will help 
to ﬁ   ll the gap between pre-existing models based on 
rodents and macaques. Further studies will evaluate the 
signiﬁ  cance and validity of this model and its suitability 
for preclinical studies.
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